(Q53662930)

17 May 2018

title

HLA alloimmunization in patients requiring ventricular assist device support. (English)

1 reference

17 May 2018

author name string

David H McKenna

1

1 reference

17 May 2018

Ted Eastlund

2

1 reference

17 May 2018

Miriam Segall

3

1 reference

17 May 2018

Harriet J Noreen

4

1 reference

17 May 2018

Soon Park

5

1 reference

17 May 2018

publication date

1 November 2002

1 reference

17 May 2018

The Journal of Heart and Lung Transplantation

published in

1 reference

17 May 2018

volume

21

1 reference

17 May 2018

issue

11

1 reference

17 May 2018

page(s)

1218-1224

1 reference

17 May 2018

Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Factors influencing HLA sensitization in implantable LVAD recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Implantable LVAD infections: implications for permanent use of the device

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Immunobiology of left ventricular assist devices

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Leukocyte Reduction in Blood Component Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

LVAD treated heart recipients do not have deleterious HLA antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Transfusion therapy and HLA antibody response in patients undergoing open heart surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

White cells in fresh-frozen plasma: evaluation of a new white cell-reduction filter

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

HLA antibodies after transfusions of FFP

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900448-5

7 January 2021

10.1016/S1053-2498(02)00448-5

Identifiers

DOI

1 reference

17 May 2018

1 reference

17 May 2018